AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

LEGN · NASDAQ · Biotechnology

Legend Biotech (ADR)

Commercializes CARVYKTI while developing next-generation CAR-T therapies.

$20.20

After-hours close+0.32 (+1.64%)

At close$19.88(−3.05%)

Something off on this page? Send us feedback.

Profile

Legend Biotech CorporationLEGNHealth Care

Commercializes CARVYKTI for multiple myeloma with Janssen and develops autologous, allogeneic, and in-vivo CAR-T programs. The business integrates cell-therapy discovery through commercialization and shares CARVYKTI economics with Janssen outside the PRC.

Commercializes CARVYKTI, a BCMA-directed autologous CAR-T therapy for multiple myeloma, with Janssen. The company integrates discovery, development, manufacturing, and commercialization; its operating footprint spans the United States, China, and Europe.

Its research portfolio covers investigational autologous, allogeneic, and in-vivo CAR-T approaches for blood cancers, solid tumors, and autoimmune diseases. LUCAR-G39D is an allogeneic candidate for B-cell non-Hodgkin lymphoma, while its in-vivo programs use the TaVec platform.

CARVYKTI is the commercial core, and its revenue, costs, and profits are shared equally with Janssen outside the PRC. Manufacturing capacity spans U.S., Chinese, and Belgian operations.

Company facts

CEOYing Huang

ListedJun 5, 2020

ExchangeNASDAQ

HeadquartersBridgewater, NJ

CountryUnited States

Employees3,100

CIK0001801198

ISINUS52490G1022

Key statistics

Market cap$3.68B

EPS (ttm)−$0.5100

P/E (ttm)−38.98

ROE-8.7%

P/B3.02

P/S2.89

Dividend yield—

Beta0.44vs XLV 0.47

Year to date −7.6% · Average volume (30d) 2.5M

Analysts

Price target, next 12 months$59.00+196.8%Median of 20 analysts · vs the Aug 28 close

ConsensusBuy15 of 20 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $19.88

High$78.00+292.4%

Median$59.00+196.8%

Low$28.00+40.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 12, 2026	Oppenheimer	Downgrade	Outperform	Perform	$75	$40
Aug 12, 2026	Barclays	Reiterate		Overweight	$94	$78
Jul 27, 2026	Raymond James	Reiterate		Outperform		$58
Jul 27, 2026	RBC Capital	Reiterate		Outperform	$63	$59
Jul 24, 2026	UBS	Downgrade	Buy	Neutral	$49	$28

Earnings

EPS

Estimate$0.02

ReportedDue Nov 11, 2026

Revenue

Estimate$361.4M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	$0.12	$0.09	−25.0%	$356.0M	$387.5M	+8.9%	+5.66%
May 12, 2026Q1 FY26	−$0.02	−$0.15	−650.0%	$306.5M	$305.1M	−0.5%	+1.45%
Mar 10, 2026Q4 FY25	−$0.17	−$0.08	+52.9%	$307.8M	$306.3M	−0.5%	+3.63%
Nov 12, 2025Q3 FY25	−$0.13	−$0.11	+15.4%	$309.5M	$272.3M	−12.0%	−0.55%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$195.1M	$255.1M	$272.3M	$306.4M	$305.1M	$387.5M
Gross profit	$123.7M	$157.1M	$157.0M	$182.9M	$129.2M	$250.1M
Operating income	−$50.6M	−$21.9M	−$43.5M	−$20.6M	−$49.8M	$57.7M
Net income	−$100.9M	−$125.4M	−$39.7M	−$30.8M	−$54.3M	$33.2M
Diluted EPS	−$0.55	−$0.68	−$0.22	−$0.17	−$0.30	$0.18
Gross margin	63.4%	61.6%	57.7%	59.7%	42.3%	64.5%
Operating margin	-26.0%	-8.6%	-16.0%	-6.7%	-16.3%	14.9%

Fiscal years (4-quarter sums)FY21 $91.2M · FY22 $108.3M · FY23 $285.1M · FY24 $627.2M · FY25 $1.03B

Revenue by geography · FY25

United States$746.1M · 97%

China$26.6M · 3%

Balance sheet, Jun 30, 2026Cash & short-term investments $964.6M · Total debt $278.2M · Total assets $1.75B · Shareholders' equity $1.23B

Dividends

No dividends on record.

Ownership

Institutions 55.89%Insiders —

Shares outstanding 184.94M · Float 178.18M · 96.4% free float

Insiders — filings are in the shares behind the receipt.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
FMR LLC	29.09M	15.73%	13F	Aug 13, 2026
Deerfield Management Company, L.P. (Series C)	8.14M	4.40%	13F	Aug 14, 2026
Suvretta Capital Management, LLC	7.07M	3.82%	13F	Aug 14, 2026
HHLR Advisors, Ltd.	5.98M	3.24%	13F	Aug 14, 2026
BlackRock, Inc.	4.73M	2.56%	13F	Aug 7, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jun 30, 2026	Patrick John Casey	director	−6,000	$14.80
Jun 25, 2026	Ying Huang	director, officer: Chief Executive Officer	−5,566	$14.78
Mar 25, 2026	Ying Huang	director, officer: Chief Executive Officer	−9,936	$8.77